1025097-55-5 Usage
Description
(R)-3-[3-fluoro-4-(4-hydroxypiperidin-4-ylmethoxy)phenyl]-5-hydroxymethyloxazolidin-2-one is a complex pharmaceutical compound characterized by a fluorine-substituted phenyl ring, a hydroxymethyloxazolidin-2-one core, and a piperidine moiety. This molecule has been synthesized and studied for its potential biological activities, particularly in the treatment of certain medical conditions. Its unique structure suggests potential interactions with biological targets that could be exploited for therapeutic purposes, making it a promising candidate for further research and development as a potential drug candidate.
Uses
Used in Pharmaceutical Industry:
(R)-3-[3-fluoro-4-(4-hydroxypiperidin-4-ylmethoxy)phenyl]-5-hydroxymethyloxazolidin-2-one is used as a potential therapeutic agent for the treatment of certain medical conditions. Its unique structure allows for potential interactions with biological targets, which could be exploited for therapeutic purposes. This makes it a promising candidate for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1025097-55-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,5,0,9 and 7 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1025097-55:
(9*1)+(8*0)+(7*2)+(6*5)+(5*0)+(4*9)+(3*7)+(2*5)+(1*5)=125
125 % 10 = 5
So 1025097-55-5 is a valid CAS Registry Number.
1025097-55-5Relevant articles and documents
Synthesis, antibacterial activities, mode of action and acute toxicity studies of new oxazolidinone-fluoroquinolone hybrids
Liu, Lili,Shao, Liping,Li, Jing,Cui, Haifeng,Li, Bing,Zhou, Xuzheng,Lv, Pengyue,Zhang, Jiyu
, (2019/05/01)
To combat bacterial resistance, a series of new oxazolidinone-fluoroquinolone hybrids have been synthesized and characterized. All synthetic hybrids were preliminarily evaluated for their in vitro antibacterial activities against 6 standard strains and 3 clinical isolates. The majority of hybrids displayed excellent activities against Gram-positive bacteria, but limited activities against Gram-negative bacteria. Hybrids OBP-4 and OBP-5 were found to be the most promising compounds. Further, in vitro antibacterial activities, mode of action and acute toxicity in mice of hybrids OBP-4 and OBP-5 were investigated. Hybrids OBP-4 and OBP-5 exhibited potent activities against Gram-positive bacteria, including drug-resistant strains. Correspondingly, studies on the mode of action of hybrids OBP-4 and OBP-5 indicated a strong inhibitory activity on protein synthesis by binding the active site of 50S subunit, but a weak inhibitory action on DNA synthesis. In addition, LD50 values of hybrids OBP-4 and OBP-5 in the acute oral toxicity were larger than 2000 mg/kg, suggesting a good safety profile.
